# Safety and Efficacy of Empagliflozin in Hemodialysis

> **NCT05786443** · PHASE2 · RECRUITING · sponsor: **NYU Langone Health** · enrollment: 60 (estimated)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05786443
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-31
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05786443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05786443, "Safety and Efficacy of Empagliflozin in Hemodialysis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05786443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*